RELX Technology (NYSE:RLX) is a consumer electronic cigarette company founded in China. Its main business is the development, design, and sales of RELX electronic cigarettes. With its advanced technology and product, its mission is to accelerate the transformation of the world’s one billion smokers, and bring to them healthier and happier lifestyles. RELX’s motto is, “Smoking can be delightful and carefree.”
RELX (NYSE:RLX) was founded in 2017, and has attracted numerous leading Venture Capital investments from Source Code Capital and IDG Capital. Currently, RELX has offices in Beijing, Shanghai, and Shenzhen, and has plans to expand internationally to better serve its global customer base. RELX’s founding team members come from renowned consumer electronics, FMCG, internet, consulting and investment companies, such as P&G, L'Oreal, Unilever, Huawei, Oppo, Mercedes-Benz, and Bain & Consulting.
XYZ Robotics was established in 2018 and is headquartered in Shanghai, China, with an R&D office in Boston, USA. The company's vision is "Pick Anything. Place Anywhere." Explore the boundaries of robotics and provide stable and efficient products. This is the dedicated pursuit of every XYZ-er.
The XYZ Robotics technical team is the only consecutive "Top 3" winner in the Amazon Robotics Challenge, for three consecutive years. With the world's leading deep learning, 3D vision, robot motion planning and other cutting-edge technologies, it provides logistics and manufacturing industries with more efficient, accurate, and easier-to-deploy flexible solutions. This includes small parts sorting, middle part de-stacking, and industrial loading and unloading.
Moody was established in 2019 as a subsidiary branch of Shanghai Moody E-commerce Co., Ltd. They are focused on creating daily or monthly fashionable color contact lenses. With sharp design, high quality products and flash sales, they want to promote an eye fashion concept for the younger generation in China. The team is composed of young experts highly conscious of consumer brands, consumer preferences, and include veterans from the fashion and beauty products industries.
METiS Pharmaceuticals is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas.
By integrating machine learning, quantum simulation, and high-throughput experimentation, we enable scientists to rapidly, comprehensively, and intelligently develop novel drug candidates.
Bota Bio is a synthetic biology company operating globally. The company builds a standardized and automated high-throughput experimental platform (Bio-foundry) that combines biological computing and machine learning to systematically engineer organisms. Committed to the development of a high-efficiency, green, low-cost industrial biological manufacturing technology suitable for large-scale production, Bota Bio provides key technical solutions for various domains such as chemicals, food, pharmaceutical and agriculture. Currently, the company’s business involves three major sectors: Biocatalysis, Biotransformation, and Biosynthesis. Its professional capabilities include biocomputing, strain engineering, and fermentation technology.
Bota Bio’s core technology and management team come from the Massachusetts Institute of Technology, Harvard University, and Amyris, Ginkgo Bioworks, Zymergen, Codexis and other top universities in the world, as well as leading companies in the field of synthetic biology. In 2020, it was selected as one of the 50 smart companies from the MIT Technology Review.
SiBionics is a MedTech startup specialized in the R&D and commercialization of active implantable medical devices and medical artificial intelligence. Our company is headquartered in Shenzhen with additional R&D center and offices located in Los Angeles, Beijing and Guangzhou.
Our project pipeline includes Retinal Prosthesis, Continuous Glucose Monitoring, Diabetic Retinopathy Screening and Gastric Cancer Screening, covering major aspects of healthcare, from health and chronic conditions management, to disease screening, diagnostics and treatment.
Today, it is increasingly recognized that more and more unmet medical needs may be met by tackling the undruggable targets in the realm of drug discovery. Along with other novel approaches, allostery has shown its potential to open another window for drug developers to broaden and diversify the drug space. Allostery is an inherent property of biomacromolecules in which topographically distinct binding sites within a protein are functionally coupled. Allosteric modulation of proteins enables exquisite control over a number of biological processes, presenting itself as a unique solution for drug developers to aim at undruggable targets. Furthermore, recent allosteric drugs, both approved and those still in clinical development stages, have simply demonstrated allostery as a proven drug discovery approach. NUTSEHLL is a suite of AI-based tools built upon a deep understanding of allosteric mechanism since 2013, when the enriched allosteric database was established around 2009. Currently, this well-established technology platform, in particular, the work flow know-how（SMA，PMA and PPA）enable to implement a complete compound discovery process from identification of the potential allosteric site, and all the way through to hit and lead molecule discovery, in conjunction with a strong medicinal chemistry capability. Thus far, NUTSHELL has been generating its own pipeline as well as enabling other academic and industry collaborators to develop allosteric drug. With our NUTSHELL proprietary platform and its early stage yet fast evolving allosteric based pipelines, NUTSHELL biotech is now becoming an oncology focused and novel target centered company and pioneering in allosteric drug discovery.
Qing Hotels helps the hotel innovation platform in the new era, providing marketing, brand building, operation, hotel talents, supply chain and system empowerment for franchised hotels. It aims to help franchisees, improve operational efficiency and operating income. Since its establishment, it has been stationed in 153 cities, 29 provinces and cities, and more than 2,700 hotels have joined. It has completed three consecutive rounds of funding from top-tier institutions and has emerged as the leader among domestic light franchise hotel chain brands.